LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Accueil・Liste d'Actions・Design Therapeutics Inc

Design Therapeutics Inc

Fermé

10.43 2.05

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

9.94

Max

10.58

Chiffres clés
By Trading Economics
Revenu	-1.6M -18M
BPA	-0.29
Employés	54
EBITDA	-1.5M -20M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+87.74% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-148M 652M
Ouverture précédente	8.38
Clôture précédente	10.43

Design Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juin 2026, 23:22 UTC

Résultats

Principaux Mouvements du Marché

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 juin 2026, 23:09 UTC

Actions en Tendance

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 juin 2026, 20:51 UTC

Résultats

Costco Reports 15% Sales Growth in May

3 juin 2026, 20:43 UTC

Résultats

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 juin 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 juin 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juin 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 juin 2026, 23:15 UTC

Market Talk

Résultats

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 juin 2026, 22:08 UTC

Actions en Tendance

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 juin 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 juin 2026, 21:18 UTC

Résultats

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 juin 2026, 21:15 UTC

Résultats

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 juin 2026, 21:13 UTC

Résultats

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 juin 2026, 21:13 UTC

Résultats

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 juin 2026, 21:12 UTC

Résultats

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 juin 2026, 21:09 UTC

Résultats

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 juin 2026, 21:03 UTC

Résultats

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 juin 2026, 20:43 UTC

Résultats

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 juin 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 juin 2026, 20:37 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 juin 2026, 20:35 UTC

Résultats

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 juin 2026, 20:17 UTC

Résultats

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 juin 2026, 20:17 UTC

Résultats

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Adj EPS $2.44 >AVGO

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q EPS $1.91 >AVGO

3 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Rev $22.19B >AVGO

Comparaison

Variation de prix

Design Therapeutics Inc prévision

Objectif de Prix

By TipRanks

87.74% hausse

Prévisions sur 12 Mois

Moyen 19.6 USD 87.74%

Haut 22 USD

Bas 15 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.